A double blind, randomized, placebo-controlled trial

Project: Research project

Project Details

Description

A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of nintedanib over 52 weeks in patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD)
StatusFinished
Effective start/end date12/20/1612/31/18

Funding

  • Boehringer-Ingelheim Pharmaceuticals

Fingerprint Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.